

DAFTAR PUSTAKA

1. Taruna Arora; Sanjana Mullangi; Manidhar Reddy Lekkala. Ovarian Cancer [Internet]. StatPearls Publishing; 2022 Jan.; 2022 [cited 2023 Mar 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567760/#_NBK567760_pubdet_
2. Cancer Facts & Figures 2022. <https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html>. 2022.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021 May;71(3):209–49.
4. Globocan 2020 : Indonesia . <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>. 2021.
5. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Vol. 11, *International Journal of Women's Health*. Dove Medical Press Ltd; 2019. p. 287–99.
6. Chang LC, Huang CF, Lai MS, Shen LJ, Wu FLL, Cheng WF. Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS One*. 2018 Mar 1;13(3).
7. Winarto H, Wijaya A, Kunci K, Penelitian A. Gambaran Mielosupresi pada Pasien Kanker Ovarium yang Menerima Kemoterapi Carboplatin-Paclitaxel di RSUPN Cipto Mangunkusumo Tahun 2018.
8. Charles A, Dewayani BM, Sahiratmadja E, Winarno GNA, Susanto H. Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients. *Universa Medicina*. 2016 Nov 30;35(3):165.
9. Medrano M, Carrillo-Cruz E, Montero I, Perez-Simon JA. Vitamin D: Effect on haematopoiesis and immune system and clinical applications. Vol. 19, *International Journal of Molecular Sciences*. MDPI AG; 2018.
10. Martens PJ, Gysemans C, Verstuyf A, Mathieu C. Vitamin d's effect on immune function. Vol. 12, *Nutrients*. MDPI AG; 2020.
11. Brown G, Kutner A, Marcinkowska E. Vitamin D and Haematopoiesis. *Curr Tissue Microenviron Rep*. 2020 Mar;1(1):1–11.
12. Zamwar UM, Anjankar AP. Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. *Cureus*. 2022 Oct 21;
13. Bethesda M. SEER Cancer Stat Facts: Ovarian Cancer. . National Cancer Institute. 2022.
14. Di Saia PJ, Creasman WT, Mannell RS, McMeekin S, Mutch DG. *Clinical Gynecologic Oncology*. 9th Edition. Dr. Scott McMeekin, editor. Philadelphia: Elsevier; 631 p.
15. Hoffman Barbara L JOSLMHCHMC and JIS. *Williams GYNECOLOGY* 4th Edition. 4th Edition. New York: New York: McGraw-Hill; 2020.
16. Khanlarkhani N, Azizi E, Amidi F, Khodarahmian M, Salehi E, Pazhohan A, et al. Metabolic risk factors of ovarian cancer: a review. Vol. 26, *Jornal Brasileiro de Reproducao Assistida*. SBRA - Associação Brasileira de Reprodução Assistida (Brazilian Society of Assisted Reproduction); 2022. p. 335–47.
17. Ladegaard Baun ML, Dueholm M, Heje HN, Hamilton W, Petersen LK, Vedsted P. Direct access from general practice to transvaginal ultrasound for early detection of ovarian cancer: a feasibility study. *Scand J Prim Health Care*. 2021;39(2):230–9.
18. Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular Biomarkers for the Early Detection of Ovarian Cancer. Vol. 23, *International Journal of Molecular Sciences*. MDPI; 2022.
19. Peter Engbersen M, Van Driel W, Lambregts D, Lahaye M. The role of CT, PET-CT, and MRI in ovarian cancer 1. 2021.
20. Gaona-Luviano P, Adriana L, Medina-Gaona, Magaña-Pérez K. Epidemiology of ovarian cancer. Vol. 9, *Chinese Clinical Oncology*. AME Publishing Company; 2020.
21. Berek JSHNF. *Berek & Hacker's Gynecologic Oncology* 7th Edition. 7th Edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ; 2021.

22. Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy [Internet]. StatPearls Publishing LLC.; 2023 [cited 2023 Jun 12]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK564367/?report=reader>
23. Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, et al. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. *Int J Gynecol Cancer*. 2021 Dec 1;31(12):1589–94.
24. Bethesda. Platinum Coordination Complexes [Internet]. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury ; 2020 [cited 2023 Jun 13]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK548788/?report=reader>
25. Tsao LR, Young FD, Otani IM, Castells MC. Hypersensitivity Reactions to Platinum Agents and Taxanes. Vol. 62, *Clinical Reviews in Allergy and Immunology*. Springer; 2022. p. 432–48.
26. Ismail U, Killeen RB. Taxane Toxicity [Internet]. 2023 [cited 2023 Jun 12]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK589655/?report=reader>
27. Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. *Dalton Transactions*. 2018;47(19):6645–53.
28. He M, Wang N, Zheng W, Cai X, Qi D, Zhang Y, et al. Ameliorative effects of ginsenosides on myelosuppression induced by chemotherapy or radiotherapy. Vol. 268, *Journal of Ethnopharmacology*. Elsevier Ireland Ltd; 2021.
29. Epstein Matti S Aapro Upal K Basu Roy Tehseen Salimi JoAnn Krenitsky Megan L Leone-Perkins Cynthia Girman Courtney Schlusser Jeffrey Crawford RS. Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors. Available from: <https://doi.org/10.6084/m9.figshare.12488759>.
30. Björn N, Jakobsen Falk I, Vergote I, Gréen H. ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients. *Basic Clin Pharmacol Toxicol*. 2018 Sep 1;123(3):277–87.
31. de Almeida LC, da Fonseca Orcina B, Maciel AP, Dos Santos D, Manzano BR, da Silva Santos PS. Severe oral mucositis relating to pain and worse oral condition among patients with solid tumors undergoing treatment with FOLFIRI and 5-FU: a retrospective study. *Sao Paulo Medical Journal*. 2022;140(4):588–94.
32. Arefa Cassoobhoy MM. Myelosuppression: Symptoms, Causes, and Treatments. <https://www.webmd.com/cancer/myelosuppression-facts#1-3>. 2023.
33. Polzonetti V, Pucciarelli S, Vincenzetti S, Polidori P. Dietary Intake of Vitamin D from Dairy Products Reduces the Risk of Osteoporosis. *Nutrients*. 2020 Jun 10;12(6).
34. Kamińska S, Pikala M, Dziankowska-Zaborszczyk E, Bielecki W, Rębowska E, Kozakiewicz K, et al. Vitamin D - dietary intake, supplementation and metabolic status of Polish adults. *Int J Occup Med Environ Health*. 2020 Jan 17;33(1):107–18.
35. Dominguez LJ, Farruggia M, Veronese N, Barbagallo M. Vitamin D Sources, Metabolism, and Deficiency: Available Compounds and Guidelines for Its Treatment. *Metabolites*. 2021 Apr 20;11(4).
36. Roseland JM, Phillips KM, Patterson KY, Pehrsson PR, Taylor CL. Chapter 60 - Vitamin D in Foods: An Evolution of Knowledge. In: Feldman D, editor. *Vitamin D (Fourth Edition)* [Internet]. Fourth Edition. Academic Press; 2018. p. 41–77. Available from: <https://www.sciencedirect.com/science/article/pii/B9780128099636000602>
37. Bruins MJ, Létinois U. Adequate Vitamin D Intake Cannot Be Achieved within Carbon Emission Limits Unless Food Is Fortified: A Simulation Study. *Nutrients*. 2021 Feb 11;13(2).
38. Chang SW, Lee HC. Vitamin D and health - The missing vitamin in humans. *Pediatr Neonatol*. 2019 Jun;60(3):237–44.
39. van Schoor N, Lips P. Global Overview of Vitamin D Status. *Endocrinol Metab Clin North Am*. 2017 Dec;46(4):845–70.

40. Outcome of a public consultation on the Draft Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on Dietary Reference Values for vitamin D. EFSA Supporting Publications [Internet]. 2016 Oct;13(10). Available from: <http://doi.wiley.com/10.2903/sp.efsa.2016.EN-1078>
41. Lou YR, Toh TC, Tee YH, Yu H. 25-Hydroxyvitamin D3 induces osteogenic differentiation of human mesenchymal stem cells. *Sci Rep*. 2017 Feb 17;7:42816.
42. Smith J, JL, BA, et al. The Role of Vitamin D in Mitigating Myelosuppression Effects in Ovarian Cancer Patients Undergoing Platinum Taxane Chemotherapy. *Journal of Oncology and Clinical Research*. 2021;
43. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Vol. 11, *International Journal of Women's Health*. Dove Medical Press Ltd; 2019. p. 287–99.
44. Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Vol. 22, *Przegląd Menopauzalny*. Termedia Publishing House Ltd.; 2023. p. 93–104.
45. Iversen L, Fielding S, Lidegaard Ø, Mørch LS, Skovlund CW, Hannaford PC. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: Prospective, nationwide cohort study. *BMJ* (Online). 2018;362.
46. Xia YY, Kotsopoulos J. Beyond the pill: contraception and the prevention of hereditary ovarian cancer. Vol. 20, *Hereditary Cancer in Clinical Practice*. BioMed Central Ltd; 2022.
47. Kamani MO, Akgor U, Gültekin M. Review of the literature on combined oral contraceptives and cancer. Vol. 16, *ecancermedicalscience*. ecancer Global Foundation; 2022.
48. Gaona-Luviano P, Adriana L, Medina-Gaona, Magaña-Pérez K. Epidemiology of ovarian cancer. Vol. 9, *Chinese Clinical Oncology*. AME Publishing Company; 2020.
49. Akin JM, Waddell JA, Solimando DA. Paclitaxel and carboplatin (TC) regimen for ovarian cancer. Vol. 49, *Hospital Pharmacy. Facts and Comparisons*; 2014. p. 425–31.
50. Madar AA, Stene LC, Meyer HE, Brekke M, Lagerløv P, Knutsen K V. Effect of vitamin D3 supplementation on iron status: A randomized, double-blind, placebo-controlled trial among ethnic minorities living in Norway. *Nutr J*. 2016;15(1).
51. Öztürk G. The effect of serum 25(OH) vitamin D on hemogram parameters. *Dicle Medical Journal / Dicle Tıp Dergisi* [Internet]. 2014 Jan 6;41(2):332–6. Available from: <http://dergipark.gov.tr/doi/10.5798/diclemedj.0921.2014.02.0426>
52. Mogire RM, Muriuki JM, Morovat A, Mentzer AJ, Webb EL, Kimita W, et al. Vitamin D Deficiency and Its Association with Iron Deficiency in African Children. *Nutrients*. 2022 Apr 1;14(7).
53. Nur-Eke R, Özen M. The Relationship between Vitamin D levels and iron deficiency and anemia in adults applied for periodic medical examination. *Clin Lab*. 2020;66(6):1019–26.
54. Keywanloo M, Ahmadi-Hamedani M, Javan JA, Zabol RF. Effects of Parenteral Vitamin D3 Supplementation on Hematological Parameters of Healthy Holstein Bulls. *Arch Razi Inst*. 2021 Nov 1;76(5):1155–63.
55. Alharbi A. A potential role of vitamin d on platelet leukocyte aggregation and pathological events in sepsis: An updated review. Vol. 14, *Journal of Inflammation Research*. Dove Medical Press Ltd; 2021. p. 3651–64.
56. Dovnik A, Dovnik NF. Vitamin D and ovarian cancer: Systematic review of the literature with a focus on molecular mechanisms. Vol. 9, *Cells*. Multidisciplinary Digital Publishing Institute (MDPI); 2020.
57. Ao T, Kikuta J, Ishii M. The effects of vitamin D on immune system and inflammatory diseases. Vol. 11, *Biomolecules*. MDPI; 2021.
58. Piatek K, Schepelmann M, Kallay E. The Effect of Vitamin D and Its Analogs in Ovarian Cancer. Vol. 14, *Nutrients*. MDPI; 2022.